Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA55557
Max Phase: Preclinical
Molecular Formula: C7H12N2O6P2
Molecular Weight: 282.13
Molecule Type: Small molecule
Associated Items:
ID: ALA55557
Max Phase: Preclinical
Molecular Formula: C7H12N2O6P2
Molecular Weight: 282.13
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1ccnc(NC(P(=O)(O)O)P(=O)(O)O)c1
Standard InChI: InChI=1S/C7H12N2O6P2/c1-5-2-3-8-6(4-5)9-7(16(10,11)12)17(13,14)15/h2-4,7H,1H3,(H,8,9)(H2,10,11,12)(H2,13,14,15)
Standard InChI Key: BAYFWSDXNJQZPY-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 282.13 | Molecular Weight (Monoisotopic): 282.0171 | AlogP: 0.44 | #Rotatable Bonds: 4 |
Polar Surface Area: 139.98 | Molecular Species: ACID | HBA: 4 | HBD: 5 |
#RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 0.87 | CX Basic pKa: 7.11 | CX LogP: -2.09 | CX LogD: -5.03 |
Aromatic Rings: 1 | Heavy Atoms: 17 | QED Weighted: 0.50 | Np Likeness Score: -0.54 |
1. Ghosh S, Chan JM, Lea CR, Meints GA, Lewis JC, Tovian ZS, Flessner RM, Loftus TC, Bruchhaus I, Kendrick H, Croft SL, Kemp RG, Kobayashi S, Nozaki T, Oldfield E.. (2004) Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo., 47 (1): [PMID:14695831] [10.1021/jm030084x] |
2. Szabo CM, Matsumura Y, Fukura S, Martin MB, Sanders JM, Sengupta S, Cieslak JA, Loftus TC, Lea CR, Lee HJ, Koohang A, Coates RM, Sagami H, Oldfield E.. (2002) Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents., 45 (11): [PMID:12014956] [10.1021/jm010412y] |
3. Szabo CM, Martin MB, Oldfield E.. (2002) An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs., 45 (14): [PMID:12086477] [10.1021/jm010279+] |
4. Martin MB, Sanders JM, Kendrick H, de Luca-Fradley K, Lewis JC, Grimley JS, Van Brussel EM, Olsen JR, Meints GA, Burzynska A, Kafarski P, Croft SL, Oldfield E.. (2002) Activity of bisphosphonates against Trypanosoma brucei rhodesiense., 45 (14): [PMID:12086478] [10.1021/jm0102809] |
5. Sanders JM, Ghosh S, Chan JM, Meints G, Wang H, Raker AM, Song Y, Colantino A, Burzynska A, Kafarski P, Morita CT, Oldfield E.. (2004) Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates., 47 (2): [PMID:14711309] [10.1021/jm0303709] |
6. Sanders JM, Gómez AO, Mao J, Meints GA, Van Brussel EM, Burzynska A, Kafarski P, González-Pacanowska D, Oldfield E.. (2003) 3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates., 46 (24): [PMID:14613320] [10.1021/jm0302344] |
7. Ling Y, Sahota G, Odeh S, Chan JM, Araujo FG, Moreno SN, Oldfield E.. (2005) Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations., 48 (9): [PMID:15857119] [10.1021/jm040132t] |
8. Prado-Prado FJ, García-Mera X, González-Díaz H.. (2010) Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species., 18 (6): [PMID:20185316] [10.1016/j.bmc.2010.01.068] |
9. Forlani G, Giberti S, Berlicki L, Petrollino D, Kafarski P.. (2007) Plant P5C reductase as a new target for aminomethylenebisphosphonates., 55 (11): [PMID:17474756] [10.1021/jf0701032] |
10. Wang K, Wang W, No JH, Zhang Y, Zhang Y, Oldfield E.. (2010) Inhibition of the Fe(4)S(4)-cluster-containing protein IspH (LytB): electron paramagnetic resonance, metallacycles, and mechanisms., 132 (19): [PMID:20426416] [10.1021/ja909664j] |
Source(1):